Completed PHASE1 INTERVENTIONAL 1-arm NCT04372407

A Study to Assess the Effect of a Strong CYP3A Inhibitor, on Surufatinib in Healthy Subjects

A Phase 1, Two Period Fixed-sequence Crossover Study to Assess the Effects of Itraconazole, a Strong CYP3A Inhibitor, on the Pharmacokinetics of Surufatinib in Healthy Subjects

Sponsor: Hutchison Medipharma Limited

Conditions Healthy

Interventions Itraconazole Surufatinib

Updated 8 times since 2020 Last updated: Feb 2, 2021 Started: Jul 9, 2020 Primary completion: Sep 29, 2020 Completion: Jan 19, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Healthy and is currently completed. Hutchison Medipharma Limited leads this study, which shows 8 recorded versions since 2020 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Nov 2022 — Jul 2024 [monthly]

Completed PHASE1
Mar 2021 — Nov 2022 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Jan 2021 — Mar 2021 [monthly]

Active Not Recruiting PHASE1

▶ Show 3 earlier versions

Dec 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE1

Status: Not Yet Recruiting → Active Not Recruiting
Aug 2020 — Dec 2020 [monthly]

Not Yet Recruiting PHASE1
Jun 2020 — Aug 2020 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hutchison Medipharma Limited

Data source: Hutchmed

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Dallas, United States